

## Prenylated and Benzylated Flavonoids from the Fruits of *Cudrania tricuspidata*

Xiang Hua Han,<sup>†</sup> Seong Su Hong,<sup>†</sup> Qinghao Jin,<sup>†</sup> Dayu Li,<sup>†</sup> Hyun-Kyu Kim,<sup>‡</sup> Jeongrae Lee,<sup>†</sup> Suk Hyung Kwon,<sup>‡</sup> Dongho Lee,<sup>§</sup> Chong-Kil Lee,<sup>†</sup> Myung Koo Lee,<sup>†</sup> and Bang Yeon Hwang<sup>\*†</sup>

College of Pharmacy, Chungbuk National University, Cheongju 361-763, Korea, Rexgene Biotech Co., Ltd., Ochang, Cheongwon, Chungbuk 363-883, Korea, and School of Life Sciences and Biotechnology, Korea University, Seoul 136-713, Korea

Received July 10, 2008


Three new prenylated isoflavones, 5,7-dihydroxy-6-(2''-hydroxy-3''-methylbut-3''-enyl)-4'-methoxyisoflavone (**1**), 5,4'-dihydroxy-6-(3''-methylbut-2''-enyl)-2'''-(4'''-hydroxy-4'''-methylethyl)-3'''-methoxydihydrofurano-[4'''',5''';7,8]isoflavone (**2**), and 5,4'-dihydroxy-8-(3''-methylbut-2''-enyl)-2'''-(4'''-hydroxy-4'''-methylethyl)furano-[4'''',5''';6,7]isoflavone (**3**), a benzylated dihydroflavonol, 5,7,4'-trihydroxy-8-*p*-hydroxybenzylidihydroflavonol (**4**), and eight known flavonoids (**5**–**12**) were isolated from the fruits of *Cudrania tricuspidata*. The structures of these compounds were determined on the basis of MS and <sup>1</sup>H and <sup>13</sup>C NMR spectroscopic data, including 2D NMR experiments. Compounds **2**, **3**, **6**, **7**, **8**, **10**, **11**, and **12** inhibited LPS-induced nitric oxide production, with IC<sub>50</sub> values of 11.8–41.8 μM.

*Cudrania tricuspidata* (carr.) Bur. (Moraceae) is a small thorny tree native to East Asia and distributed mainly in the southern part of Korea. The cortex and root bark of this plant has been used for the treatment of gonorrhea, jaundice, hepatitis, neuritis, and inflammation.<sup>1</sup> Several prenylated xanthenes and flavonoids,<sup>2–6</sup> isolated from the root of the genus *Cudrania*, were found to have cytotoxic,<sup>7–10</sup> antifungal,<sup>11</sup> antioxidant,<sup>12</sup> antiatherosclerotic,<sup>13</sup> anti-inflammatory,<sup>13</sup> and hepatoprotective<sup>14,15</sup> activities and display monoamine oxidase inhibitory effects.<sup>16,17</sup>

As part of our ongoing research program for the discovery of plant-derived inhibitors of nitric oxide (NO) production, we found that CH<sub>2</sub>Cl<sub>2</sub> and EtOAc extracts of the fruits of *C. tricuspidata* inhibited NO production in RAW 264.7 cells. We isolated three new prenylated isoflavones and a new benzylated dihydroflavonol, together with eight known flavonoids, and the structures were determined on the basis of MS as well as <sup>1</sup>H NMR, <sup>13</sup>C NMR, and 2D NMR data. We describe herein the isolation, structure determination, and inhibitory effects of NO production in murine macrophage RAW 264.7 cells.

Fresh fruits of *C. tricuspidata* were extracted with MeOH and successively fractionated with CH<sub>2</sub>Cl<sub>2</sub>, EtOAc, and H<sub>2</sub>O. Repeated column chromatography (CC) and semipreparative HPLC of the CH<sub>2</sub>Cl<sub>2</sub>- and EtOAc-soluble extracts resulted in the isolation of three new prenylated isoflavones (**1**–**3**) and a benzylated dihydroflavonol (**4**), together with eight known compounds (**5**–**12**). The eight known compounds were identified as 5,3'-dihydroxy-4'-methoxy-2'',2''-dimethylpyrano-(5'',6'';6,7)-isoflavone (**5**),<sup>18</sup> erysenegalensein E (**6**),<sup>19</sup> isoerysenegalensein E (**7**),<sup>20</sup> senegalensin (**8**),<sup>21,22</sup> gericudranin D (**9**),<sup>23</sup> 5,7,4'-trihydroxy-6,8-diprenylisoflavone (**10**),<sup>24</sup> orobol (**11**),<sup>25</sup> and gericudranin E (**12**)<sup>23</sup> by comparison of spectroscopic data with reported values in the literature.

Compound **1** was obtained as pale yellow needles. The molecular formula was determined to be C<sub>21</sub>H<sub>20</sub>O<sub>6</sub> by HRFABMS. The <sup>1</sup>H and <sup>13</sup>C NMR spectra of compound **1** were similar to those of laburnetin,<sup>26</sup> except for an additional signal arising from an OCH<sub>3</sub> group. The <sup>1</sup>H NMR spectrum had a sharp singlet at δ<sub>H</sub> 7.83 and a downfield signal at δ<sub>H</sub> 13.25, confirming the presence of an intramolecular hydrogen-bonded group at the C-5 position of an isoflavone skeleton. An aromatic proton signal at δ<sub>H</sub> 6.46 (1H, s,



H-8), an OCH<sub>3</sub> signal at δ<sub>H</sub> 3.84 (3H, s), and two sets of doublet signals for the AA'BB' spin system at δ<sub>H</sub> 6.97 and 7.44 (each 2H, d, J = 8.5 Hz) were assigned to a *p*-disubstituted benzene ring. The presence of a 2-hydroxy-3-methyl-3-butenyl group was deduced from the <sup>1</sup>H NMR signals of two benzylic proton signals at δ<sub>H</sub> 2.92 and 3.17 (each 1H, dd, J = 7.8 and 14.9 Hz), an oxymethine proton signal at δ<sub>H</sub> 4.41 (1H, br d, J = 7.8 Hz), two olefinic *gem*-proton signals at δ<sub>H</sub> 4.88 and 4.99 (each 1H, br s), and a methyl proton signal at δ<sub>H</sub> 1.86 (3H, s). The <sup>13</sup>C NMR and DEPT spectra of compound **1** showed 21 carbon signals including an isoflavone moiety with a methoxy and a 2-hydroxy-3-methyl-3-butenyl group. In the HMBC experiment, the OCH<sub>3</sub> at δ<sub>H</sub> 3.84 (3H, s) was correlated with C-4' at δ<sub>C</sub> 159.7, which suggested that the OCH<sub>3</sub> group is located at C-4'. HMBC correlations of the benzylic proton signals (δ<sub>H</sub> 2.92 and 3.17) with C-5 (δ<sub>C</sub> 160.3), C-6 (δ<sub>C</sub> 109.2), and C-7 (δ<sub>C</sub> 163.1) indicated that the 2-hydroxy-3-methyl-3-butenyl group was attached to C-6 of the A-ring. Complete assignment of the <sup>1</sup>H, <sup>13</sup>C NMR chemical shifts was obtained using <sup>1</sup>H–<sup>1</sup>H COSY, HMQC, DEPT, and HMBC NMR correlations (see Experimental

\* Corresponding author. Tel: +82-43-261-2814. Fax: +82-43-268-2732. E-mail: byhwang@chungbuk.ac.kr.

<sup>†</sup> Chungbuk National University.

<sup>‡</sup> Rexgene Biotech Co., Ltd.

<sup>§</sup> Korea University.

Section). Thus, compound **1** was identified as 5,7-dihydroxy-6-(2''-hydroxy-3''-methylbut-3''-enyl)-4'-methoxyisoflavone.

Compound **2** showed a molecular ion peak at  $m/z$  453.1914 [ $M + H$ ]<sup>+</sup> (HRFABMS), corresponding to a molecular formula of C<sub>26</sub>H<sub>28</sub>O<sub>7</sub>. The <sup>1</sup>H NMR spectrum had a sharp singlet at δ<sub>H</sub> 8.37 and a downfield signal at δ<sub>H</sub> 13.87 that were characteristic of a 5-hydroxyisoflavone skeleton. Two sets of doublet signals at δ<sub>H</sub> 7.63 (2H, d,  $J = 8.5$  Hz) and 7.06 (2H, d,  $J = 8.5$  Hz) were assigned to a *p*-disubstituted benzene, as found in the B-ring. A group of signals at δ<sub>H</sub> 5.43 (1H, d,  $J = 7.2$  Hz), 3.52 and 3.45 (each 1H, dd,  $J = 7.2$  and 14.1 Hz), 1.93 (3H, s), and 1.81 (3H, s) suggested the presence of a 3-methylbut-3-enyl (prenyl) group in the molecule. Furthermore, two singlet methyl signals (δ<sub>H</sub> 1.51 and 1.28), two oxygenated methine signals at δ<sub>H</sub> 5.46 (1H, d,  $J = 2.1$  Hz) and 4.71 (1H, d,  $J = 2.1$  Hz), and an OCH<sub>3</sub> signal (δ<sub>H</sub> 3.61) indicated a dihydrofuran ring with a 2-(1-hydroxy-1-methylethyl)-3-methoxy substituted group. The HMBC correlations particularly from the OCH<sub>3</sub> signal at δ<sub>H</sub> 3.61 to C-3''' (δ<sub>C</sub> 79.8) supported the attachment of the OCH<sub>3</sub> group at C-3''', and correlations from H-2''' (δ<sub>H</sub> 4.71) to C-7 (δ<sub>C</sub> 166.8) and C-3''' (δ<sub>C</sub> 79.8) as well as correlations from the H-3''' (δ<sub>H</sub> 5.46) to C-7 (δ<sub>H</sub> 166.8) and C-8 (δ<sub>C</sub> 104.9) indicated the location of a 2-(1-hydroxy-1-methylethyl)-3-methoxy-2,3-dihydrofuran ring at the C-7 and C-8 positions of the A-ring. The position of the prenyl group was determined as C-6 according to the HMBC correlation of H-1'' (δ<sub>H</sub> 3.52 and 3.45) to C-5 (δ<sub>C</sub> 162.4), C-6 (δ<sub>C</sub> 108.0), and C-7 (δ<sub>C</sub> 166.8). All of the NMR assignments were obtained using <sup>1</sup>H-<sup>1</sup>H COSY, HMQC, DEPT, and HMBC correlations. The relative configuration of the two oxygenated methine protons on the dihydrofuran ring was determined to be *trans* by a comparison of the coupling constant between H-2''' and H-3''' ( $J = 2.1$  Hz).<sup>27</sup> The strong NOE correlations observed between H-3''' (δ<sub>H</sub> 5.46) and the two methyl protons at δ<sub>H</sub> 1.51 and 1.28 in the NOESY spectrum further supported the *trans* relationship. Thus, compound **2** was identified as 5,4'-dihydroxy-6-(3''-methylbut-2''-enyl)-2'''-(4''''-hydroxy-4''''-methylethyl)-3'''-methoxydihydrofurano-[4''',5''';7,8]isoflavone.

Compound **3** was obtained as a yellow powder. The molecular formula of **3** was determined to be C<sub>25</sub>H<sub>24</sub>O<sub>6</sub> by HRFABMS. The <sup>1</sup>H NMR signals at δ<sub>H</sub> 8.01 and 13.40 were also characteristic of a 5-hydroxyisoflavone. The <sup>1</sup>H and <sup>13</sup>C NMR data of **3** were similar to those of **2**, except for the presence of signals for the 1-hydroxy-1-methylethylfuran ring at δ<sub>H</sub> 6.81 (1H, s, H-3'''), 1.70 (3H, s, CH<sub>3</sub>-6'''), and 1.26 (3H, s, CH<sub>3</sub>-5'''); δ<sub>C</sub> 162.9 (C-2'''), 98.4 (C-3'''), 69.2 (C-4'''), 29.7 (C-6'''), and 25.8 (C-5''') instead of the 2-(1-hydroxy-1-methylethyl)-3-methoxy-2,3-dihydrofuran ring present in **2**. The location of a 1-hydroxy-1-methylethylfuran ring was determined to be at the C-6 and C-7 positions of the A-ring on the basis of HMBC correlations between H-3''' (δ<sub>H</sub> 6.81) and C-6 (δ<sub>C</sub> 113.4) and C-7 (δ<sub>C</sub> 157.4). HMBC correlations of the benzylic proton signal (δ<sub>H</sub> 3.69) with C-7 (δ<sub>C</sub> 157.4), C-8 (δ<sub>C</sub> 104.0), and C-8a (δ<sub>C</sub> 151.1) indicated that the prenyl group was attached to C-8 of the A-ring. Therefore, compound **3** was identified as 5,4'-dihydroxy-8-(3''-methylbut-2''-enyl)-2'''-(4''''-hydroxy-4''''-methyl-ethyl)furan-[4''',5''';6,7]isoflavone.

Compound **4** showed a [ $M + H$ ]<sup>+</sup> peak at  $m/z$  395.1136 (HRFABMS), corresponding to the molecular formula C<sub>22</sub>H<sub>18</sub>O<sub>7</sub>. The <sup>1</sup>H and <sup>13</sup>C NMR spectroscopic data of **4** were similar to those reported for gericudranin E.<sup>23</sup> The <sup>1</sup>H NMR spectrum of **4** showed two sets of proton signals at δ<sub>H</sub> 7.57 (2H, d,  $J = 8.4$  Hz) and 7.05 (2H, d,  $J = 8.4$  Hz), typical of an AA'BB' system of a *p*-substituted ring B, and two AB systems at δ<sub>H</sub> 5.23 (1H, d,  $J = 11.5$  Hz) and 4.75 (1H, d,  $J = 11.5$  Hz) characteristic of *trans* diaxial H-2 and H-3 protons of a dihydroflavonol, and a proton signal at δ<sub>H</sub> 6.26 (1H, s) assignable to H-6 or H-8 of ring A. The spectrum also showed the presence of a *p*-substituted benzyl group at δ<sub>H</sub> 7.21 (2H, d,  $J = 8.3$  Hz), 6.80 (2H, d,  $J = 8.3$  Hz), 3.91 (1H, d,  $J = 14.0$  Hz), and 3.84 (1H, d,  $J = 14.0$  Hz). The structure was also

**Table 1.** Inhibition of NO Production by Compounds **1–12**<sup>a</sup>

compound	IC <sub>50</sub> (μM)	compound	IC <sub>50</sub> (μM)
<b>1</b>	>50	<b>8</b>	13.1 ± 0.12
<b>2</b>	11.8 ± 0.28	<b>9</b>	>50
<b>3</b>	12.1 ± 0.21	<b>10</b>	19.2 ± 0.21
<b>4</b>	>50	<b>11</b>	18.7 ± 0.14
<b>5</b>	>50	<b>12</b>	41.8 ± 0.27
<b>6</b>	18.4 ± 0.17	AG <sup>b</sup>	28.0 ± 0.25
<b>7</b>	12.7 ± 0.16		

<sup>a</sup>Data are presented as a mean ± SD from three separate experiments. <sup>b</sup>Aminoguanidine was used as the positive control.

supported by the <sup>13</sup>C NMR, DEPT, and HMQC spectra. The position of a *p*-substituted benzyl group was confirmed by the HMBC correlations. The benzylic methylene protons at δ<sub>H</sub> 3.91 and 3.84 showed long-range correlations with C-7 (δ<sub>C</sub> 165.3), C-8 (δ<sub>C</sub> 109.1), and C-8a (δ<sub>C</sub> 160.8). The absolute configuration of **4** was determined by measurement of the CD spectrum, which showed a positive Cotton effect at 326 nm and a negative Cotton effect at 294 nm, which are characteristic of 2*R*, 3*R* absolute stereochemistry.<sup>28</sup> Therefore, compound **4** was identified as 5,7,4'-trihydroxy-8-*p*-hydroxybenzylidihydroflavonol.

All of the isolates (**1–12**) were evaluated for their inhibitory effects of LPS-induced NO production in RAW 264.7 cells. Compounds **2**, **3**, **6**, **7**, **8**, **10**, **11**, and **12** significantly inhibited LPS-induced NO production with IC<sub>50</sub> values of 11.8–41.8 μM (Table 1). Cell viability, as measured by the CCK assay, indicated that none of the compounds had significant cytotoxicity at concentrations that could inhibit NO production (data not shown). These results indicate that the fruits of *C. tricuspidata* may be useful for the treatment of inflammatory diseases caused by excessive production of NO.

## Experimental Section

**General Experimental Procedures.** Melting points were measured on Büchi model B-540 without correction. Optical rotations were determined with a JASCO DIP-1000 polarimeter. CD spectra were recorded on a JASCO J-715 spectrometer. UV and IR spectra were obtained on JASCO UV-550 and Perkin-Elmer model LE599 spectrometers, respectively. NMR spectra were recorded on a Bruker DRX 500 MHz NMR spectrometer using CDCl<sub>3</sub> and acetone-*d*<sub>6</sub> as solvents. High-resolution fast atom bombardment (HRFAB) and electron impact (EI) mass spectra were obtained on JMS 700 (JEOL, Tokyo, Japan) and VG Autospec Ultima (Micromass, Manchester, UK) mass spectrometers, respectively. Semipreparative HPLC was performed using a Waters HPLC system equipped with two Waters 515 pumps, a 2996 photodiode array detector, and Millennium 32 software using a YMC J'sphere ODS-H80 column (4 μm, 150 × 20 mm, i.d., flow rate 6.5 mL/min). Silica gel (70–230 mesh, Merck, Germany) and Sephadex LH-20 (25–100 μm, Amersham Biosciences, Sweden) were used for open column chromatography (CC). Thin-layer chromatography (TLC) was performed on a precoated silica gel 60 F<sub>254</sub> (0.25 mm, Merck, Germany). All other chemicals and reagents were analytical grade. Fetal bovine serum, media, and supplement materials for cell culture were purchased from Gibco BRL (Grand Island, NY).

**Plant Material.** Fruits of *C. tricuspidata* were collected from the herb garden at Chungbuk National University, Cheongju, Korea, in October 2005. The plant material was identified by Emeritus Professor Kyong Soon Lee. A voucher specimen of this plant was deposited at the Herbarium of the College of Pharmacy, Chungbuk National University, Korea (CBNU 05021).

**Extraction and Isolation.** The fresh fruits of *C. tricuspidata* (4.1 kg) were sliced and extracted with MeOH (3 × 8 L) at room temperature. The solvent was evaporated *in vacuo* to afford a MeOH extract (D01, 120 g), which was then suspended in H<sub>2</sub>O (1.5 L). The aqueous solution was partitioned with CH<sub>2</sub>Cl<sub>2</sub> (3 × 1.5 L) and EtOAc (3 × 1.5 L), sequentially, to afford dried CH<sub>2</sub>Cl<sub>2</sub>- (D02, 41.7 g), EtOAc- (D03, 13.5 g), and H<sub>2</sub>O-soluble (D04, 62.5 g) residues. Bioassay indicated that the CH<sub>2</sub>Cl<sub>2</sub>- and EtOAc-soluble extracts showed significant inhibitory effects on LPS-induced NO production with IC<sub>50</sub> values of 17.2 and 28.6 μg/mL, respectively. Accordingly, the CH<sub>2</sub>Cl<sub>2</sub>-soluble

fraction was separated on a silica gel column eluted with CH<sub>2</sub>Cl<sub>2</sub>/MeOH (1:0 to 1:1, then pure MeOH) to yield five fractions (CT-C1–CT-C5). Fraction CT-C4 was further purified by silica gel CC eluted with hexane/acetone (10:1 to 1:1, then pure acetone) to give four subfractions (CT-C41–CT-C44). Fraction CT-C42 was separated by semipreparative HPLC using CH<sub>3</sub>CN/H<sub>2</sub>O (65:35, v/v) to yield compounds **1** (6.5 mg) and **5** (3.6 mg). Fraction CT-C43 was passed over a silica gel column and eluted with a gradient of hexane/CH<sub>2</sub>Cl<sub>2</sub> (2:1 to 0:1) and CH<sub>2</sub>Cl<sub>2</sub>/MeOH (1:0 to 0:1) to afford four subfractions (CT-C431–CT-C434). Fraction CT-C431 was purified by semipreparative HPLC using CH<sub>3</sub>CN/H<sub>2</sub>O (60:40, v/v) to yield compounds **2** (5.9 mg) and **8** (6.8 mg). Fraction CT-C432 was further purified by semipreparative HPLC using CH<sub>3</sub>CN/H<sub>2</sub>O (65:35, v/v) to yield compounds **6** (5.9 mg) and **7** (6.8 mg). Fraction CT-C44 was further separated over silica gel eluted with CH<sub>2</sub>Cl<sub>2</sub>/acetone (3:1 to 1:1) to give compound **3** (5.3 mg). Fraction CT-C5 was purified by silica gel CC eluted with CH<sub>2</sub>Cl<sub>2</sub>/EtOAc (5:1 to 0:1) to give three subfractions (CT-C51–CT-C53). Fraction CT-C52 was further separated over Sephadex LH-20 eluted with MeOH to afford four subfractions (CT-C521–CT-C524). Fraction CT-C522 was purified by semipreparative HPLC using CH<sub>3</sub>CN/H<sub>2</sub>O (65:35, v/v) to furnish compound **4** (3.5 mg). Fraction CT-C523 was further purified by semipreparative HPLC using CH<sub>3</sub>CN/H<sub>2</sub>O (60:40, v/v) to yield compound **9** (3.9 mg).

The EtOAc fraction was separated on a silica gel column eluted with CH<sub>2</sub>Cl<sub>2</sub>/MeOH (1:0 to 1:1, then pure MeOH) to yield six fractions (CT-E1–CT-E6). Fraction CT-E2 was passed through Sephadex LH-20 eluted with MeOH and purified by semipreparative HPLC using CH<sub>3</sub>CN/H<sub>2</sub>O (55:45, v/v) to afford compound **10** (1.9 mg). Fraction CT-E4 was separated by Sephadex LH-20 eluted with MeOH and further purified by semipreparative HPLC using CH<sub>3</sub>CN/H<sub>2</sub>O (50:50, v/v) to yield compounds **11** (6.5 mg) and **12** (5.0 mg).

**5,7-Dihydroxy-6-(2''-hydroxy-3''-methylbut-3''-enyl)-4'-methoxyisoflavone (1):** pale yellow needles; mp 208–210 °C; [α]<sub>D</sub><sup>25</sup> +4.44 (c 0.19, MeOH); UV (MeOH) λ<sub>max</sub> nm (log ε) 265.4 (4.5); IR ν<sub>max</sub> (dried film) 3433, 2081, 1639, 1247, 582 cm<sup>-1</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 500 MHz) δ 13.25 (1H, s, 5-OH), 7.83 (1H, s, H-2), 7.44 (2H, d, J = 8.7 Hz, H-2', 6'), 6.97 (2H, d, J = 8.7 Hz, H-3', 5'), 6.46 (1H, s, H-8), 4.99 (1H, s, Ha-4''), 4.88 (1H, s, Hb-4''), 4.41 (1H, d, J = 7.8 Hz, H-2''), 3.84 (3H, s, OCH<sub>3</sub>-4'), 3.17 (1H, dd, J = 7.8, 14.9 Hz, Ha-1''), 2.92 (1H, dd, J = 7.8, 14.9 Hz, Hb-1''), 1.86 (3H, s, CH<sub>3</sub>-5''); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 125 MHz) δ 180.9 (C-4), 163.1 (C-7), 160.3 (C-5), 159.7 (C-4'), 156.7 (C-8a), 152.6 (C-2), 136.6 (C-3''), 130.2 (C-2', 6'), 123.4 (C-1'), 123.3 (C-3), 114.1 (C-3', 5'), 110.5 (C-4''), 109.2 (C-6), 105.6 (C-4a), 95.2 (C-8), 77.5 (C-2''), 55.4 (-OCH<sub>3</sub>), 28.2 (C-1''), 18.6 (C-5''); EIMS m/z 368 [M]<sup>+</sup>; HRFABMS m/z 369.1333 [M + H]<sup>+</sup> (calcd for C<sub>21</sub>H<sub>21</sub>O<sub>6</sub>, 369.1338).

**5,4'-Dihydroxy-6-(3''-methylbut-2''-enyl)-2'''-(4'''-hydroxy-4'''-methylethyl)-3'''-methoxydihydrofurano-[4''',5''',7,8]isoflavone (2):** yellow powder; mp 156–158 °C; [α]<sub>D</sub><sup>25</sup> +1.38 (c 0.12, MeOH); UV (MeOH) λ<sub>max</sub> nm (log ε) 217.0 (4.6), 265.4 (4.4); IR ν<sub>max</sub> (dried film) 3460, 1647 cm<sup>-1</sup>; <sup>1</sup>H NMR (acetone-d<sub>6</sub>, 500 MHz) δ 13.87 (1H, s, 5-OH), 8.37 (1H, s, H-2), 7.63 (2H, d, J = 8.5 Hz, H-2', 6'), 7.06 (2H, d, J = 8.5 Hz, H-3', 5'), 5.46 (1H, d, J = 2.1 Hz, H-3'''), 5.43 (1H, t, J = 7.2 Hz, H-2''), 4.71 (1H, d, J = 2.1 Hz, H-2'''), 4.12 (1H, s, OH-4'''), 3.61 (3H, s, OCH<sub>3</sub>-3'''), 3.52 (1H, dd, J = 7.2, 14.2 Hz, Ha-1''), 3.45 (1H, dd, J = 7.2, 14.2 Hz, Hb-1''), 1.93 (3H, s, CH<sub>3</sub>-4''), 1.81 (3H, s, CH<sub>3</sub>-5''), 1.51 (3H, s, 5'''-Me), 1.28 (3H, s, 6'''-Me); <sup>13</sup>C NMR (acetone-d<sub>6</sub>, 125 MHz) δ 181.8 (C-4), 166.8 (C-7), 162.4 (C-5), 158.5 (C-4'), 153.8 (C-2), 153.2 (C-8a), 132.3 (C-3''), 131.3 (C-2', 6'), 124.3 (C-3), 123.1 (C-1'), 122.4 (C-2''), 116.0 (C-3', 5'), 108.0 (C-6), 106.4 (C-4a), 104.9 (C-8), 97.3 (C-2''), 79.8 (C-3'''), 71.0 (C-4'''), 56.3 (-OCH<sub>3</sub>), 27.1 (C-6'''), 25.8 (C-4''), 24.4 (C-5'''), 22.2 (C-1''), 17.9 (C-5''); EIMS m/z 452 [M]<sup>+</sup>; HRFABMS m/z 453.1914 [M + H]<sup>+</sup> (calcd for C<sub>26</sub>H<sub>29</sub>O<sub>7</sub>, 453.1914).

**5,4'-Dihydroxy-8-(3''-methylbut-2''-enyl)-2'''-(4'''-hydroxy-4'''-methylethyl)-furano-[4''',5''',6,7]isoflavone (3):** yellow powder; mp 160–162 °C; UV (MeOH) λ<sub>max</sub> nm (log ε) 268.9 (4.6); IR ν<sub>max</sub> (dried film) 3435, 1631, 604 cm<sup>-1</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 500 MHz) δ 13.40 (1H, s, 5-OH), 8.01 (1H, s, H-2), 7.44 (2H, d, J = 7.3 Hz, H-2', 6'), 6.91 (2H, d, J = 7.3 Hz, H-3', 5'), 6.81 (1H, s, H-3'''), 5.33 (1H, t, J = 7.1 Hz, H-2''), 3.69 (2H, d, J = 7.1 Hz, H-1''), 1.87 (3H, s, 5'''-Me), 1.70 (3H, s, 4'''-Me), 1.70 (3H, s, 6'''-Me), 1.26 (3H, s, 5'''-Me); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 125 MHz) δ 182.9 (C-4), 162.9 (C-2'''), 157.4 (C-7), 153.4 (C-2, C-5), 151.1 (C-8a), 132.8 (C-3''), 130.4 (C-4'), 123.3 (C-2', 6'),

122.4 (C-3, C-1'), 121.1 (C-2''), 115.6 (C-3', 5'), 113.4 (C-6), 106.8 (C-4a), 104.0 (C-8), 98.4 (C-3'''), 69.2 (C-4'''), 29.7 (C-6'''), 28.6 (C-4''), 25.8 (C-5'''), 22.2 (C-1''), 17.9 (C-5''); HRFABMS m/z 421.1653 [M + H]<sup>+</sup> (calcd for C<sub>25</sub>H<sub>25</sub>O<sub>6</sub>, 421.1651).

**5,7,4'-Trihydroxy-8-p-hydroxybenzylidihydroflavonol (4):** yellow powder; mp 126–128 °C; [α]<sub>D</sub><sup>25</sup> +30.81 (c 0.03, MeOH); UV (MeOH) λ<sub>max</sub> nm (log ε) 296.2 (4.3); CD (c 0.01, MeOH) [θ]<sub>260</sub> +4905, [θ]<sub>294</sub> -9734, [θ]<sub>326</sub> +4822; IR ν<sub>max</sub> (dried film) 3439, 1635, 609 cm<sup>-1</sup>; <sup>1</sup>H NMR (acetone-d<sub>6</sub>, 500 MHz) δ 11.81 (1H, s, 5-OH), 7.57 (2H, d, J = 8.4 Hz, H-2', 6'), 7.21 (2H, d, J = 8.3 Hz, H-3', 7''), 7.05 (2H, d, J = 8.4 Hz, H-3', 5'), 6.80 (2H, d, J = 8.3 Hz, H-4', 6''), 6.26 (1H, s, H-6), 5.23 (1H, d, J = 11.5 Hz, H-2), 4.75 (1H, d, J = 11.5 Hz, H-3), 3.91 (1H, d, J = 14.0 Hz, Ha-1''), 3.84 (1H, d, J = 14.0 Hz, Hb-1''); <sup>13</sup>C NMR (acetone-d<sub>6</sub>, 125 MHz) δ 198.3 (C-4), 165.3 (C-7), 162.6 (C-5), 160.8 (C-8a), 158.5 (C-4'), 156.0 (C-5''), 132.7 (C-2''), 130.1 (C-3', 7''), 129.7 (C-2', 6'), 129.1 (C-1'), 115.6 (C-3', 5'), 115.3 (C-4', 6''), 109.1 (C-8), 101.3 (C-4a), 96.5 (C-6), 84.0 (C-2), 73.0 (C-3), 27.5 (C-1''); EIMS m/z 394 [M]<sup>+</sup>; HRFABMS m/z 395.1136 [M + H]<sup>+</sup> (calcd for C<sub>22</sub>H<sub>19</sub>O<sub>7</sub>; 395.1131).

**Determination of NO Production and Cell Viability.** The level of nitric oxide production was determined by measuring the amount of nitrite in the cell culture supernatant as previously described.<sup>29</sup> The viability of the cells remaining after the Griess assay was determined using a CCK-8 assay as previously described.<sup>29</sup>

**Acknowledgment.** This work was supported by a grant from the Korea Research Foundation Grant funded by the Korea Government (MOCIE) (Chungbuk QOL grant). The authors wish to thank the Korea Basic Science Institute for the NMR spectroscopic measurements.

## References and Notes

- Jung, B. S.; Shin, M. K. *Encyclopedia of Illustrated Korean Natural Drugs*; Young Lim Sa: Seoul, 1990; pp 544–545.
- Zou, Y. S.; Hou, A. J.; Zhu, G. F. *Chem. Biodiversity* **2005**, *2*, 131–138.
- Hano, Y.; Matsumoto, Y.; Shinohara, K.; Sun, J. Y.; Nomura, T. *Planta Med.* **1991**, *57*, 172–175.
- Hano, Y.; Matsumoto, Y.; Sun, J. Y.; Nomura, T. *Planta Med.* **1990**, *56*, 478–481.
- Hano, Y.; Matsumoto, Y.; Sun, J. Y.; Nomura, T. *Planta Med.* **1990**, *56*, 399–402.
- Fujimoto, T.; Hano, Y.; Nomura, T. *Planta Med.* **1984**, *50*, 218–221.
- Lee, I. K.; Kim, C. J.; Song, K. S.; Kim, H. M.; Koshino, H.; Uramoto, M.; Yoo, I. D. *Phytochemistry* **1996**, *41*, 213–216.
- Zou, Y. S.; Hou, A. J.; Zhu, G. F.; Chen, Y. F.; Sun, H. D.; Zhao, Q. S. *Bioorg. Med. Chem.* **2004**, *12*, 1947–1953.
- Lee, B. W.; Gal, S. W.; Park, K. M.; Park, K. H. *J. Nat. Prod.* **2005**, *68*, 456–458.
- Sun, N. J.; Chang, C. J.; Cassady, J. M. *Phytochemistry* **1988**, *27*, 951–952.
- Wang, Y. H.; Hou, A. J.; Zhu, G. F.; Chen, D. F.; Sun, H. D. *Planta Med.* **2005**, *71*, 273–274.
- Lee, B. W.; Lee, J. H.; Lee, S. T.; Lee, H. S.; Lee, W. S.; Jeong, T. S.; Park, K. H. *Bioorg. Med. Chem. Lett.* **2005**, *15*, 5548–5552.
- Park, K. H.; Park, Y. D.; Han, J. M.; Im, K. R.; Lee, B. W.; Jeong, I. Y.; Jeong, T. S.; Lee, W. S. *Bioorg. Med. Chem. Lett.* **2006**, *16*, 5580–5583.
- An, R. B.; Sohn, D. H.; Kim, Y. C. *Biol. Pharm. Bull.* **2006**, *29*, 838–840.
- Tian, Y. H.; Kim, H. C.; Cui, J. M.; Kim, Y. C. *Arch. Pharm. Res.* **2005**, *28*, 44–48.
- Hwang, J. H.; Hong, S. S.; Han, X. H.; Hwang, J. S.; Lee, D.; Lee, H.; Yun, Y. P.; Kim, Y.; Ro, J. S.; Hwang, B. Y. *J. Nat. Prod.* **2007**, *70*, 1207–1209.
- Han, X. H.; Hong, S. S.; Hwang, J. S.; Jeong, S. H.; Hwang, J. H.; Lee, M. H.; Lee, M. K.; Lee, D.; Ro, J. S.; Hwang, B. Y. *Arch. Pharm. Res.* **2005**, *28*, 1324–1327.
- Olivares, E. M.; Lwande, W.; Monache, F. D.; Bettolo, G. B. M. *Phytochemistry* **1982**, *21*, 1763–1765.
- Wandji, J.; Fomum, Z. T.; Tillequin, F.; Seguin, E.; Koch, M. *Phytochemistry* **1994**, *35*, 245–248.
- El-Masry, S.; Amer, M. E.; Abdel-Kader, M. S.; Zaatout, H. H. *Phytochemistry* **2002**, *60*, 783–787.
- Wandji, J.; Nkengfack, A. E.; Fomum, Z. T.; Ubillas, R.; Killday, K. B.; Tempesta, M. S. *J. Nat. Prod.* **1990**, *53*, 1425–1429.
- Tanaka, H.; Doi, M.; Etoh, H.; Watanabe, N.; Shimizu, H.; Hirata, M.; Ahmad, M.; Qurashi, I.; Khan, M. R. *J. Nat. Prod.* **2001**, *64*, 1336–1440.

- (23) Lee, I. K.; Kim, C. J.; Song, K. S.; Kim, H. M.; Yoo, I. D.; Koshino, H.; Esumi, Y.; Uramoto, M. *J. Nat. Prod.* **1995**, *58*, 1614–1617.
- (24) Shirataki, Y.; Manaka, A.; Komatsu, M. *Phytochemistry* **1982**, *21*, 2959–2963.
- (25) El-Sohly, H. N.; Joshi, A.; Li, X. C.; Ross, S. A. *Phytochemistry* **1999**, *52*, 141–145.
- (26) Sato, H.; Tahara, S.; Ingham, J. L.; Dziedzic, S. Z. *Phytochemistry* **1995**, *39*, 673–676.
- (27) Takashima, J.; Ohsaki, A. *J. Nat. Prod.* **2002**, *65*, 1843–1847.
- (28) Islam, M. T.; Tahara, S. *Phytochemistry* **2000**, *54*, 901–907.
- (29) Hong, S. S.; Lee, S. A.; Han, X. H.; Hwang, J. S.; Lee, C.; Lee, D.; Hong, J. T.; Kim, Y.; Lee, H.; Hwang, B. Y. *J. Nat. Prod.* **2008**, *71*, 1055–1058.

NP800418J